JNJ vs PFE
Johnson & Johnson vs Pfizer Inc. · Updated Nov 13, 2026
JNJ — 13 winsPFE — 10 wins
Price Performance
JNJ +46.35%PFE +12.02%
Performance
| JNJ | PFE | |
|---|---|---|
| 1 Month | +11.92% | -0.87% |
| 3 Months | +9.15% | +8.08% |
| 6 Months | +23.13% | +12.45% |
| YTD | +37.32% | +16.29% |
| 1 Year | +46.61% | +13.50% |
| 3 Year | +75.85% | -15.04% |
| 5 Year | +75.43% | -21.68% |
Yearly Returns
| YTD | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| JNJ | +37.8% | +43.7% | -9.6% | -12.0% | +3.0% | +9.3% | +7.8% | +14.2% | -7.3% | +20.6% | +14.7% | -1.7% |
| PFE | +14.7% | -6.4% | -10.8% | -43.8% | -9.4% | +60.4% | -0.8% | -9.4% | +19.8% | +9.8% | +1.6% | +3.0% |
Valuation
| JNJ | PFE | |
|---|---|---|
| P/E Ratio | 32.85 | 22.10 |
| Forward P/E | 11.17 | 9.08 |
| PEG Ratio | 2.75 | -3.95 |
| P/S Ratio | 7.01 | 2.65 |
| P/B Ratio | 8.31 | 1.86 |
| EV/EBITDA | 21.22 | 13.77 |
Financials
| JNJ | PFE | |
|---|---|---|
| EPS (TTM) | $8.65 | $1.31 |
| Gross Margin | +71.49% | +67.26% |
| Operating Margin | +26.58% | +27.90% |
| Net Margin | +21.76% | +18.60% |
| ROE | +25.92% | +8.31% |
| ROA | +10.47% | +3.61% |
| Debt/Equity | 0.22 | 0.72 |
Growth
| JNJ | PFE | |
|---|---|---|
| Revenue Growth YoY | +9.91% | +5.37% |
| Revenue Growth QoQ | -2.04% | -17.69% |
| EPS Growth YoY | -52.86% | -9.55% |
| EPS Growth QoQ | +1.90% | +262.07% |
Technical
| JNJ | PFE | |
|---|---|---|
| RSI (14) | 64.54 | 46.81 |
| % From 20-Day SMA | +5.24% | -2.92% |
| % From 50-Day SMA | +6.55% | +0.54% |
| % From 200-Day SMA | +13.90% | +7.36% |
| % From 52-Week High | -0.66% | -7.90% |
| % From 52-Week Low | +47.19% | +22.59% |
Analyst Ratings
JNJ
Buy(24 analysts)
Strong SellHoldStrong Buy
Price Target
$285.31
+3.75% upside
PFE
Hold(18 analysts)
Strong SellHoldStrong Buy
Price Target
$31.13
+6.46% upside
Overview
| JNJ | PFE | |
|---|---|---|
| Sector | Healthcare | Healthcare |
| Industry | Drug Manufacturers - General | Drug Manufacturers - General |
| Exchange | NYSE | NYSE |
| Market Cap | $675.03B | $167.86B |
| Shares Outstanding | 2.41B | 5.70B |
| Avg Volume (10D) | 7.93M | 43.32M |
| Dividend Yield | 1.88% | 5.84% |
Frequently Asked Questions
Is JNJ or PFE a better buy right now?
Based on 23 comparable metrics, JNJ leads in 13 categories while PFE leads in 10. JNJ has a consensus analyst rating with 24 analysts covering the stock. Neither stock should be purchased based on a single comparison — consider your investment goals and risk tolerance.
Which stock has better performance, JNJ or PFE?
Over the past year, JNJ returned +46.61% compared to PFE's +13.50%. In the short term (1 month), JNJ returned +11.92% vs PFE's -0.87%.
Is JNJ or PFE more expensive?
JNJ trades at a P/E of 32.85 compared to PFE's 22.10. On a price-to-sales basis, JNJ trades at 7.01x vs PFE's 2.65x. Forward P/E: JNJ at 11.17 vs PFE at 9.08.
Which stock has higher growth, JNJ or PFE?
JNJ's revenue grew +9.91% year-over-year compared to PFE's +5.37%. EPS growth: JNJ at -52.86% vs PFE at -9.55%.
Do JNJ and PFE pay dividends?
JNJ pays a dividend with a yield of 1.88%. PFE pays a dividend with a yield of 5.84%.
Which stock do analysts prefer, JNJ or PFE?
JNJ has 24 analysts with a target price of $285.31 (+3.75% upside). PFE has 18 analysts with a target of $31.13 (+6.46% upside).
Data updated daily. All comparisons based on latest available market data. Not investment advice.